ABL DiagnosticsXPAR:ABLD +0.75%50 Days Inventory is 582.05 as of Dec. 2025, which is 7% above its 10-year median of 543.93. GuruFocus rates XPAR:ABLD with a GF Score™ of 50/100 and a GF Value™ of €7.72 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 493 Healthcare Providers & Services companies, ABL Diagnostics ranks worse than 98.99% on this metric.
The historical rank and industry rank for ABL Diagnostics's Days Inventory or its related term are showing as below:
XPAR:ABLD'
s Days Inventory Range Over the Past 10 Years
Min: 340.67 Med: 543.93 Max: 1028.59
Current: 993.43
During the past 13 years, ABL Diagnostics's highest Days Inventory was 1028.59. The lowest was 340.67. And the median was 543.93.
XPAR:ABLD's Days Inventory is ranked worse than 98.99% of 493
companies
in the Healthcare Providers & Services industry
Industry Median: 30.04
vs XPAR:ABLD: 993.43
ABL Diagnostics's Days Inventory
increased
from Dec. 2024 (0.00) to Dec. 2025 (582.05).
It might indicate that ABL Diagnostics's sales slowed down.
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
ABL Diagnostics's Inventory Turnover for the
six
months ended in Dec. 2025 was 0.31.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
ABL Diagnostics's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.24.
ABL Diagnostics (XPAR:ABLD) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
ABL Diagnostics's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
ABL Diagnostics's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
ABL Diagnostics Days Inventory Related Terms
ABL Diagnostics Days Inventory Historical Data
* Premium members only.
The historical data trend for ABL Diagnostics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ABLD vs VEEV, BTSG, TEM: Days Inventory Comparison
For the Health Information Services subindustry, ABL Diagnostics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics Days Inventory vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's Days Inventory distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABL Diagnostics (XPAR:ABLD) has a Days Inventory of 582.05 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on ABL Diagnostics and its competitors. This is near median its historical median of 543.93. Over the past decade, ABL Diagnostics' Days Inventory has ranged from 340.67 to 1,028.59. According to the industry distribution chart, ABL Diagnostics ranks #488 out of 493 companies in the Healthcare Providers & Services industry, placing it in the top 99%.
Is ABL Diagnostics' Days Inventory too high?
ABL Diagnostics' current Days Inventory of 582.05 is near median its 10-year median of 543.93. Over the past 10 years, this metric has ranged from a low of 340.67 to a high of 1,028.59. The Healthcare Providers & Services industry median Days Inventory is 30.04. ABL Diagnostics' value of 582.05 is 1837.6% above this industry median. Based on the distribution chart, ABL Diagnostics ranks #488 out of 493 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, ABL Diagnostics has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' Days Inventory compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #488 out of 493 companies for Days Inventory. This places ABL Diagnostics in the lower half of its industry. The industry median Days Inventory is 30.04. ABL Diagnostics' value of 582.05 is 1837.6% above this benchmark. Historically, ABL Diagnostics' own Days Inventory has ranged from 340.67 to 1,028.59 over the past decade. While the company's 10-year median is 543.93 vs. the industry median of 30.04, ABL Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Healthcare Providers & Services company?
The median Days Inventory among Healthcare Providers & Services companies is 30.04, based on 493 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABL Diagnostics's current Days Inventory of 582.05 is 1837.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on ABL Diagnostics and its competitors. For the Healthcare Providers & Services industry, the median Days Inventory is 30.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current Days Inventory is 582.05, which is near median its own 10-year median of 543.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.72, compared to a current price of €2.68 — trading 65.3% below its estimated fair value. The current Days Inventory is 582.05, which is near median its 10-year median of 543.93 and 1837.6% above the Healthcare Providers & Services industry median of 30.04. ABL Diagnostics' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current Days Inventory is 582.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.68 is trading 65.3% below its estimated GF Value™ of €7.72.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for XPAR:ABLD:
Days Inventory: 582.05 (near median its 10-year median of 543.93)
GF Value™: €7.72 vs. price of €2.68 (65.3% below fair value)
Industry Position: 1837.6% above the Healthcare Providers & Services median (#488 of 493)
No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
50GF Score
Get the complete analysis for XPAR:ABLD
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ABLD has been successfully added to your 
